Analysts Anticipate Proteon Therapeutics, Inc. (PRTO) Will Post Earnings of -$0.40 Per Share
Equities analysts expect Proteon Therapeutics, Inc. (NASDAQ:PRTO) to post ($0.40) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Proteon Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.52) and the highest estimate coming in at ($0.34). Proteon Therapeutics reported earnings per share of ($0.43) during the same quarter last year, which suggests a positive year-over-year growth rate of 7%. The company is scheduled to report its next quarterly earnings report on Monday, November 6th.
According to Zacks, analysts expect that Proteon Therapeutics will report full year earnings of ($1.54) per share for the current year, with EPS estimates ranging from ($1.72) to ($1.42). For the next year, analysts anticipate that the company will post earnings of ($1.64) per share, with EPS estimates ranging from ($1.81) to ($1.35). Zacks’ EPS calculations are an average based on a survey of research firms that cover Proteon Therapeutics.
Proteon Therapeutics (NASDAQ:PRTO) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.11.
PRTO has been the subject of several recent analyst reports. HC Wainwright set a $3.00 price objective on shares of Proteon Therapeutics and gave the stock a “hold” rating in a research report on Saturday, May 13th. Oppenheimer Holdings, Inc. reissued a “market perform” rating on shares of Proteon Therapeutics in a research report on Wednesday, August 16th. Cowen and Company restated a “hold” rating on shares of Proteon Therapeutics in a research note on Tuesday, August 8th. Zacks Investment Research cut Proteon Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Finally, Maxim Group set a $6.00 price objective on Proteon Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 4th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $8.00.
Proteon Therapeutics (NASDAQ:PRTO) traded up 1.923% on Tuesday, reaching $1.325. 11,664 shares of the company’s stock traded hands. Proteon Therapeutics has a 52-week low of $1.10 and a 52-week high of $11.45. The firm’s 50-day moving average is $1.35 and its 200 day moving average is $1.50. The stock’s market capitalization is $23.35 million.
COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Proteon Therapeutics, Inc. (PRTO) Will Post Earnings of -$0.40 Per Share” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/25/analysts-anticipate-proteon-therapeutics-inc-prto-will-post-earnings-of-0-40-per-share.html.
An institutional investor recently bought a new position in Proteon Therapeutics stock. RA Capital Management LLC bought a new position in Proteon Therapeutics, Inc. (NASDAQ:PRTO) during the second quarter, according to its most recent disclosure with the SEC. The fund bought 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics makes up about 0.2% of RA Capital Management LLC’s holdings, making the stock its 22nd largest position. RA Capital Management LLC owned about 7.59% of Proteon Therapeutics as of its most recent filing with the SEC. 41.08% of the stock is currently owned by hedge funds and other institutional investors.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related stocks with our FREE daily email newsletter.